文献速递白内障与屈光手术眼底病与葡萄膜炎

PANK4通过YAP调控LEC糖酵解通路驱动早期糖尿病性白内障LEC-EMT

PANK4 Regulates YAP to Modulate the Glycolytic Pathway in LEC for Driving LECs-EMT in Early Diabetic Cataract Pathogenesis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究探讨PANK4在糖尿病性白内障(DC)中的作用机制。在糖尿病小鼠和高糖刺激的晶状体上皮细胞(LEC)中,PANK4与EMT标志物显著上调;PANK4过表达上调EMT标志物和YAP,免疫共沉淀证实PANK4与YAP存在物理互作。敲低PANK4或抑制YAP可抑制α-SMA和YAP表达、促进LEC增殖并减少迁移,且si-PANK4或YAP抑制剂可减轻糖尿病小鼠前囊膜损伤。高糖和PANK4过表达上调HK2、LDHA及YAP/TAZ,而PANK4敲低和YAP抑制均逆转这些效应。结论提示PANK4-YAP-糖酵解-EMT轴是DC的潜在治疗靶点。

要点

  • 糖尿病小鼠和高糖LEC中PANK4与EMT标志物显著上调,PANK4过表达上调YAP。
  • 敲低PANK4或抑制YAP可抑制α-SMA和YAP、促进LEC增殖并减少迁移。
  • si-PANK4或YAP抑制剂可减轻糖尿病小鼠前囊膜损伤。

核心结论

  • 高糖下PANK4激活YAP/TAZ通路上调糖酵解酶HK2/LDHA,驱动LEC-EMT和早期DC进展。
  • 体内抑制PANK4或YAP可减轻前囊膜损伤,提示PANK4-YAP-糖酵解-EMT轴是DC的潜在治疗靶点。

研究设计与样本

  • 建立糖尿病小鼠和高糖刺激的LEC模型,干预包括PANK4过表达/敲低和YAP抑制剂处理。
  • 采用Western blotting和免疫荧光分析蛋白表达,免疫共沉淀验证PANK4-YAP物理互作。
  • 糖尿病小鼠前房注射si-PANK4或YAP抑制剂后,用裂隙灯评估前囊膜损伤。
  • LEC功能实验包括EdU、鬼笔环肽染色和划痕愈合实验。

主要发现

  • 糖尿病小鼠中PANK4和EMT标志物显著上调,PANK4过表达上调LEC中EMT标志物和YAP。
  • 免疫共沉淀证实PANK4与YAP在晶状体中存在物理互作。
  • PANK4敲低和高糖刺激的晶状体抑制α-SMA和YAP表达,增强LEC增殖并减少迁移。
  • si-PANK4或YAP抑制减轻糖尿病小鼠诱导的前囊膜损伤。
  • 高糖和PANK4过表达上调HK2、LDHA和YAP/TAZ,PANK4敲低和YAP抑制均逆转这些效应。

关键数值与推荐

  • PANK4敲低后si-PANK4显著下调EMT标志物和YAP,并逆转晶状体中YAP的磷酸化状态。
  • PANK4过表达LEC中YAP抑制剂处理同样下调EMT/YAP标志物,并重现si-PANK4在晶状体中的功能效应。

临床怎么用

  • PANK4-YAP-糖酵解-EMT轴可作为糖尿病性白内障的潜在治疗靶点。
  • 抑制PANK4或YAP可能减轻糖尿病性白内障早期前囊膜损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lens epithelial cell-mesenchymal transition (LEC-EMT) is the key process in diabetic cataract (DC). Although PANK4 is known to suppress LEC-EMT, its mechanism remains unclear. This study aims to elucidate the role of PANK4 in DC pathogenesis through the YAP/TAZ pathway. METHODS: We established diabetic mice and high-glucose-stimulated LECs. Interventions included PANK4 overexpression/knockdown and YAP inhibitor treatment. Protein expression was analyzed by Western blotting and immunofluorescence. Anterior capsule damage was assessed via slit-lamp after anterior chamber injection of si-PANK4 or YAP inhibitor in diabetic mice. LECs' functional assays included EdU, phalloidin staining, and scratch-wound assays. RESULTS: PANK4 and EMT markers were significantly upregulated in diabetic mice, and PANK4-overexpression upregulated EMT markers and YAP in LECs. Immunoprecipitation confirmed PANK4-YAP physical interaction in the lens. PANK4-knockdown of LECs and high-glucose-stimulated lens suppressed the expression of α-SMA and YAP, enhanced LECs' proliferation, and reduced the migration. Most importantly, si-PANK4 or YAP inhibition alleviated induced anterior capsule damage in diabetic mice. The si-PANK4 significantly downregulated EMT markers and YAP, and reversed the phosphorylation state of YAP in the lens. YAP inhibitor treatment in PANK4-overexpressing LECs similarly downregulated EMT/YAP markers and replicated the functional effects of si-PANK4 in the lens. High glucose and PANK4-overexpression upregulated HK2, LDHA, and YAP/TAZ expression, and both PANK4-knockdown and YAP inhibition reversed these effects. CONCLUSIONS: Under hyperglycemia, PANK4 activates the YAP/TAZ pathway to upregulate glycolytic enzymes (HK2/LDHA), driving LEC-EMT and early DC progression. In vivo inhibition of PANK4 or YAP alleviates anterior capsule damage, highlighting the PANK4-YAP-glycolysis-EMT axis as a promising therapeutic target for DC.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Li X, Luo L, Chen S, et al. PANK4 Regulates YAP to Modulate the Glycolytic Pathway in LEC for Driving LECs-EMT in Early Diabetic Cataract Pathogenesis. Invest Ophthalmol Vis Sci. 2026. PMID: 42047666. doi:10.1167/iovs.67.4.66

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。